MOVIPREP 2.691 G
SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G · DIN 02359499 · ARALEZ PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is MOVIPREP?
MOVIPREP 2.691 G contains SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G. It is listed in the Health Canada Drug Product Database under DIN 02359499, held by ARALEZ PHARMACEUTICALS CANADA INC, supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Aug-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MOVIPREP used for?
Cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02359499 |
|---|---|
| Brand name | MOVIPREP |
| Generic / active ingredient | SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G |
| Manufacturer | ARALEZ PHARMACEUTICALS CANADA INC |
| Strength | 2.691 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | A06AD65 MACROGOL, COMBINATIONS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Aug-2020 |
How is it administered?
Adults: 2 litres of reconstituted solution. Can be taken as split-dose (1L evening before, 1L morning of) or full-dose (2L evening before). Drink 1L additional clear fluid.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted solution should be used within 24 hours; can be refrigerated. (Note: Specific powder storage temp not in provided text snippet).
How is it supplied?
One pack contains 2 transparent bags, each containing one Sachet A and one Sachet B. Sufficient for a single treatment (2 litres).
Contraindications
Hypersensitivity; GI obstruction/perforation; gastric emptying disorders (e.g. gastroparesis); ileus; toxic megacolon; toxic colitis; acute surgical abdominal conditions; unconscious patients.
Warnings and precautions
Risk of fluid/electrolyte shifts, cardiac arrhythmias, seizures, and ischemic colitis. Contains aspartame (phenylalanine). Risk of G6PD deficiency hemolysis.
What can be used instead?
Other Canadian products sharing ATC code A06AD65 MACROGOL, COMBINATIONS. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COLYTE | 10.65 MG | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00677442 |
| JAMPLYTE | 22.96 G / 280 G | POWDER | JAMP PHARMA CORPORATION | MARKETED | DIN 02378329 |
| JAMP-ELECTROPEG | 2.97 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | DIN 02406780 |
| JAMP-ELECTROPEG WITH FLAVOUR PACKET | 2.97 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | DIN 02406799 |
| JAMPLYTE | 0.76 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | DIN 02368234 |
| KLEAN-PREP | 1.68 G | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02147793 |
| PLENVU | 9 G | KIT ; POWDER FOR SOLUTION | BAUSCH HEALTH, CANADA INC. | CANCELLED PRE MARKET | DIN 02550938 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.